Sector News

Pfizer plots $200M consolidation for St. Louis employees

November 23, 2016
Life sciences

With development support from the state of Missouri and local governments, Pfizer plans to centralize 450 of its St. Louis employees, plus add 80 new jobs, at a planned $200 million R&D site.

Upon the facility’s expected completion in 2020, the company will move its employees in the area from “two sites and multiple buildings” to one location in Chesterfield, a St. Louis Suburb.

The site will be designed for R&D in vaccines, immuno-oncology drugs, monoclonal antibodies and biosims, according to a statement from the St. Louis Economic Development Partnership.

Having operated in the area for more than 13 years, Pfizer is “very proud of the world class employee base we’ve built here,” a spokesperson told FiercePharma.

Development incentives from the state will be contingent on “strict job creation criteria,” with construction set to begin next year. The company received additional assistance from the county and city for the $200 million project.

Local developers CRG and Clayco will build and own the facility with Pfizer planning to sign a lease to operate there.

For the pharma giant, the move in St. Louis comes as it looks to move corporate headquarters in New York City, a spokesperson said last month. The company hopes to begin relocating to “a new, more modern” Manhattan HQ by the middle of 2019.

The St. Louis consolidation also comes on the heels of the company’s Q3 earnings that fell 38% to $1.32 billion.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach